Stage 3 Pleural Mesothelioma: Inoperable Disease, Immunotherapy, and the Active Trial Landscape

A pathology report that reads “Stage III” is one of the more disorienting moments in a mesothelioma diagnosis. The cancer is locally advanced. The surgical team may have already said no, or said probably not. The conversation shifts from operative planning to systemic therapy and trial enrollment, often in the same appointment.

This guide is for someone newly told their disease is Stage III and trying to understand what that label actually changes about the path forward. It explains how the AJCC 9th edition defines IIIA and IIIB, why most Stage III disease is inoperable, what the first-line immunotherapy trials showed in this population, and which clinical trials are open. It does not rank options as universally better, because the trial evidence does not support that ranking.

For background on staging itself, see the pleural mesothelioma overview and the treatment options hub. For the parallel guides at the other ends of the staging spectrum, see Stage 1 pleural mesothelioma on operable disease and Stage 2 pleural mesothelioma on the borderline-operable decision.

What Stage III Means: IIIA, IIIB, and the T and N Descriptors

The AJCC Cancer Staging Manual 9th edition, effective for cases diagnosed from 2025 onward, builds on the IASLC Mesothelioma Staging Project and refines the T descriptors with quantitative pleural-thickness measurements alongside the older anatomic criteria. Stage III splits into two substages.

Stage IIIA is generally T3 disease with N0 or N1 nodal status. T3 indicates locally advanced tumor that invades a single adjacent structure, such as the chest wall, diaphragm, or endothoracic fascia, or shows multifocal visceral pleural involvement. N0 means no regional nodal disease; N1 means ipsilateral bronchopulmonary or hilar nodes. Some IIIA cases are still evaluated for surgical resection at high-volume centers, particularly when the T3 invasion is focal and the patient has favorable performance status.

Stage IIIB is either T4 disease (any nodal status) or T3 disease with N2 nodal involvement. T4 is the most extensive local-invasion category, including diffuse pleural involvement, contralateral pleural extension, or invasion of mediastinal structures, spine, heart, or trachea. N2 means ipsilateral mediastinal or subcarinal nodes, and especially multistation N2 involvement. The combination of T4 anatomy or multistation N2 nodal disease is what shifts a case from “consider surgery” to “systemic therapy is the spine of treatment.”

The 9th edition also introduced quantitative imaging metrics. CT-measured maximum pleural thickness (Fmax greater than 5 mm in the fissure, for example) is now part of the T-descriptor logic, refining what used to be a more subjective anatomic call. Treatment teams use the AJCC criteria together with the surgeon’s assessment of resectability rather than reading the stage label in isolation.

Why Most Stage III Disease Is Inoperable

Inoperable does not mean untreatable. It means the surgical team has determined that a macroscopic complete resection (sometimes called R0 or R1, depending on the surgical taxonomy used at the center) is not achievable. Two patterns drive that decision in Stage III.

The first is anatomy. T4 disease that has crossed into the contralateral pleura, the mediastinum, the spine, or the pericardium cannot be removed without leaving gross disease behind. The benefit of surgery in mesothelioma comes from cytoreduction to a microscopic disease state, and that benefit collapses when gross residual disease is unavoidable.

The second is nodal involvement. Multistation N2 disease, meaning two or more separate ipsilateral mediastinal or subcarinal nodal stations involved, has consistently been associated with poor outcomes after surgery in pleural mesothelioma series. Most academic mesothelioma programs treat multistation N2 as a contraindication to operative cytoreduction, even when the primary tumor is technically resectable.

A third practical factor is the patient. Performance status, pulmonary function, cardiac reserve, and comorbidities can make an extrapleural pneumonectomy or extended pleurectomy and decortication unsafe even when the tumor anatomy is borderline. Stage III is the population where the decision is most often not surgical, but the reasoning behind that decision varies and deserves a clear explanation from the surgical team.

First-Line Immunotherapy at Stage III: The CheckMate-743 and IND.227 Trials

Both pivotal modern first-line trials enrolled adults with unresectable pleural mesothelioma rather than restricting to a single AJCC stage. The trial populations therefore include a mix of Stage III and Stage IV patients, and the published efficacy results apply to the unresectable population as a whole. Neither primary publication isolates a Stage III subgroup with a separately reported hazard ratio, so the most defensible thing a Stage III patient can take from these trials is the trial-wide result.

CheckMate-743 (Baas et al., The Lancet, 2021) was a phase 3 open-label randomized trial of 605 patients with previously untreated unresectable pleural mesothelioma. Patients were randomized 1:1 to nivolumab plus ipilimumab for up to two years versus six cycles of pemetrexed plus cisplatin or carboplatin. Median overall survival was 18.1 months on dual checkpoint blockade versus 14.1 months on chemotherapy (HR 0.74; 95% CI 0.61 to 0.89; p=0.002). The 5-year update by Scherpereel and colleagues in the Journal of Clinical Oncology in 2026 confirmed durable benefit, with 5-year overall survival of 14% on nivolumab plus ipilimumab versus 6% on chemotherapy, and no new safety signals. The October 2020 FDA approval of nivolumab plus ipilimumab for unresectable pleural mesothelioma rested on the original Lancet data.

The histology-stratified results from CheckMate-743 are particularly relevant at Stage III. In the non-epithelioid subgroup (sarcomatoid and biphasic combined), median overall survival was 18.8 months on nivolumab plus ipilimumab versus 8.8 months on chemotherapy (HR 0.46; 95% CI 0.30 to 0.70). In epithelioid disease, the medians were 18.2 versus 16.2 months (HR 0.85; 95% CI 0.66 to 1.10), a smaller and statistically non-significant subgroup difference. For a person with Stage III disease and confirmed sarcomatoid or biphasic histology, this is one of the strongest pieces of randomized evidence in the modern first-line literature, and it argues for chemotherapy-free dual checkpoint blockade.

IND.227 / KEYNOTE-483 (Chu et al., The Lancet, 2024) was a Canadian Cancer Trials Group-led phase 2/3 randomized trial of pembrolizumab plus pemetrexed-platinum versus pemetrexed-platinum chemotherapy alone in advanced pleural mesothelioma. Median overall survival was 17.3 months on the pembrolizumab combination versus 16.1 months on chemotherapy alone (HR 0.79; 95% CI 0.64 to 0.98). The trial supported the September 17, 2024 FDA approval. The chemotherapy control arm in IND.227 outperformed the chemotherapy arm in CheckMate-743, so cross-trial comparison of the immunotherapy arms is not valid. IND.227 keeps chemotherapy in the backbone, which oncology teams have the most operational experience delivering.

For the side-by-side framing of how teams choose between these two regimens at the unresectable threshold, see the first-line treatment decision guide.

Chemotherapy Considerations When Immunotherapy Is Not the Right Fit

Both pivotal trials excluded patients with active autoimmune disease requiring systemic immunosuppression, untreated central nervous system metastases, and interstitial lung disease. A person with significant inflammatory bowel disease, active lupus or rheumatoid arthritis on biologic therapy, or a history of severe pneumonitis may not be a candidate for either checkpoint inhibitor regimen.

In that situation, the most-supported chemotherapy-only first-line option is the MAPS triplet of bevacizumab plus pemetrexed and cisplatin, established by Zalcman and colleagues in The Lancet in 2016. MAPS reported median overall survival of 18.8 months versus 16.1 months without bevacizumab (HR 0.77; 95% CI 0.62 to 0.95) in advanced pleural mesothelioma. The triplet requires adequate renal function for cisplatin and adequate vascular health for bevacizumab.

Pemetrexed plus a platinum agent without bevacizumab, the older Vogelzang regimen from 2003, remains an option for patients who cannot tolerate bevacizumab. Carboplatin substitutes for cisplatin in patients with reduced renal function or hearing concerns, and the National Cancer Institute Mesothelioma Treatment summary lists the carboplatin-pemetrexed pairing as accepted.

Clinical Trials Currently Open at Stage III

Stage III is one of the populations where trial enrollment is most often a reasonable first step rather than a fallback after standard treatment fails. Several categories of trials currently enroll patients with unresectable disease.

Adoptive cell therapy

A phase 2 trial at UPMC Hillman Cancer Center (NCT03935893) is testing autologous tumor-infiltrating lymphocyte (TIL) therapy plus high-dose aldesleukin in locally advanced, recurrent, or metastatic cancers including mesothelioma. Coverage of the TIL cell therapy phase 2 trial explains the lymphodepleting preparative regimen and eligibility.

Multiple trials test pembrolizumab, atezolizumab, and other PD-1/PD-L1 agents in combination or as post-chemo maintenance. A phase 3 atezolizumab trial sponsored by Gruppo Oncologico Italiano di Ricerca Clinica (NCT04996017) is recruiting people in the post-resection setting, illustrating the breadth of immunotherapy questions still under active study.

Anti-mesothelin CAR-T and antibody-drug conjugates target a high-density surface antigen on epithelioid mesothelioma. Several CAR-T programs (BASECAMP-1 / EVEREST-2, the Memorial Sloan Kettering and Penn anti-mesothelin programs) are open in heavily pretreated populations, and mesothelin-targeted antibody-drug conjugates such as anetumab ravtansine remain under investigation.

Novel-mechanism programs round out the trial landscape. ADI-PEG20 (the ATOMIC-meso phase 3 program) targets argininosuccinate synthetase 1 deficiency in non-epithelioid disease. Tumor-treating fields, gene therapy, and oncolytic virus programs continue to enroll in selected centers.

A practical search of ClinicalTrials.gov by location and by current treatment status is the most reliable way to find an open Stage III trial, because the landscape changes month by month.

Practical Questions for the Oncology Team

Stage III pleural mesothelioma is, in most cases, a setting where the team is choosing between active systemic options rather than considering surgery as a real possibility. The most useful thing the oncology team can do is make the reasoning behind a specific recommendation visible and to spell out a plan for what comes next if the first regimen does not work.

The reviewer for this guide, Dr. Hedy Kindler, directs the Multidisciplinary Mesothelioma Program at the University of Chicago and has written and spoken extensively about first-line systemic therapy and clinical trial design in advanced mesothelioma. The clinical-trial landscape evolves quickly enough that what is true at diagnosis may not be true six months later, and a planned re-review of trial options at first restaging is a reasonable expectation to set with the team.

For broader context on the systemic therapy landscape, see the first-line treatment decision guide and the clinical trial enrollment guide.

Frequently Asked Questions